Shares of Outlook Therapeutics (NASDAQ: OTLK) jumped on Tuesday after the biotech announced positive clinical trial results for its investigational treatment for neovascular age-related macular degeneration (wet AMD). Outlook Therapeutics' treatment for wet AMD, which is known as ONS-5010/Lytenava (bevacizumab), reached its primary efficacy endpoint in a phase 3 study. A statistically significant 41% of the patients who were treated with bevacizumab gained at least 15 letters in the best-corrected visual acuity (BCVA) at 11 months.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting